BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

888 related articles for article (PubMed ID: 16826479)

  • 1. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
    Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
    J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
    Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
    Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid core peptide technology and group A streptococcal vaccine delivery.
    Olive C; Batzloff MR; Toth I
    Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
    Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
    J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
    Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
    Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
    Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
    J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
    Olive C; Clair T; Yarwood P; Good MF
    Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens.
    Olive C; Batzloff M; Horváth A; Clair T; Yarwood P; Toth I; Good MF
    Infect Immun; 2003 May; 71(5):2373-83. PubMed ID: 12704107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage.
    Horváth A; Olive C; Karpati L; Sun HK; Good M; Toth I
    J Med Chem; 2004 Jul; 47(16):4100-4. PubMed ID: 15267249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
    Mannam P; Jones KF; Geller BL
    Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation.
    Moyle PM; Olive C; Ho MF; Good MF; Toth I
    J Med Chem; 2006 Oct; 49(21):6364-70. PubMed ID: 17034142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines.
    Simerska P; Abdel-Aal AB; Fujita Y; Moyle PM; McGeary RP; Batzloff MR; Olive C; Good MF; Toth I
    J Med Chem; 2008 Mar; 51(5):1447-52. PubMed ID: 18278857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
    Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
    BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes.
    Schulze K; Olive C; Ebensen T; Guzmán CA
    Vaccine; 2006 Aug; 24(35-36):6088-95. PubMed ID: 16828529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus.
    Batzloff MR; Yan H; Davies MR; Hartas J; Lowell GH; White G; Burt DS; Leanderson T; Good MF
    J Infect Dis; 2005 Oct; 192(8):1450-5. PubMed ID: 16170764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Method for the synthesis of highly pure vaccines using the lipid core peptide system.
    Moyle PM; Olive C; Good MF; Toth I
    J Pept Sci; 2006 Dec; 12(12):800-7. PubMed ID: 17131293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus.
    Marasini N; Khalil ZG; Giddam AK; Ghaffar KA; Hussein WM; Capon RJ; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Int J Pharm; 2016 Nov; 513(1-2):410-420. PubMed ID: 27659862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain.
    Schulze K; Medina E; Guzmán CA
    Vaccine; 2006 Feb; 24(9):1446-50. PubMed ID: 16289766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes.
    Bessen D; Fischetti VA
    J Immunol; 1990 Aug; 145(4):1251-6. PubMed ID: 1696296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.